Cyclophosphamide 99% Powder CAS NO (50-18-0) Industrial Grade

Mechanism of Action:

• Cyclophosphamide is converted in the liver by cytochrome P450 enzymes into its active metabolites, phosphoramide mustard, and acrolein.
• Phosphoramide mustard is the active cytotoxic metabolite responsible for cross-linking DNA strands, leading to DNA damage and inhibition of cell proliferation.
• Cyclophosphamide primarily targets rapidly dividing cells, including cancer cells, but it can also affect normal cells with high proliferation rates, such as bone marrow and gastrointestinal epithelium.

Indications:

• Cyclophosphamide is used in the treatment of various cancers, including lymphomas, leukemia, multiple myeloma, breast cancer, ovarian cancer, and lung cancer.
• It is also employed in the management of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and vasculitis.

Dosage Forms:

• Cyclophosphamide is available in oral and intravenous formulations. It may be administered as tablets, capsules, or as a sterile lyophilized powder for reconstitution.

Dosage and Administration:

• The dosage of cyclophosphamide varies depending on the indication, patient's body weight, renal function, and other factors.
• It is typically administered in divided doses over several days in combination with other chemotherapy agents, often as part of a multidrug regimen.

Adverse Effects:

• Common adverse effects of cyclophosphamide include myelosuppression (bone marrow suppression), leading to neutropenia, thrombocytopenia, and anemia.
• Other adverse effects may include nausea, vomiting, mucositis, alopecia, hemorrhagic cystitis, and increased susceptibility to infections.
• Long-term use of cyclophosphamide may be associated with an increased risk of secondary malignancies, infertility, and cardiopulmonary toxicity.

Monitoring:

• Patients receiving cyclophosphamide therapy require regular monitoring of blood cell counts, renal function, liver function, and electrolyte levels.
• Close monitoring for signs of infection, hemorrhagic cystitis, and other adverse effects is essential during treatment.

Drug Interactions:

• Cyclophosphamide may interact with other medications, including other chemotherapeutic agents, immunosuppressants, and drugs that affect liver metabolism or renal function.
• Concurrent use of cyclophosphamide with nephrotoxic or myelosuppressive agents may increase the risk of adverse effects.

Contraindications:

• Cyclophosphamide is contraindicated in patients with a history of severe bone marrow suppression, hypersensitivity to cyclophosphamide or its components, and urinary outflow obstruction.
• It should be used with caution in patients with renal impairment, hepatic dysfunction, or preexisting infections.

Pregnancy and Lactation:

• Cyclophosphamide is classified as Pregnancy Category D due to its potential teratogenic effects and fetal harm. It should be avoided during pregnancy whenever possible, and adequate contraception is recommended for patients of childbearing potential.
• Breastfeeding is not recommended during cyclophosphamide therapy due to the potential risk of adverse effects in nursing infants.